Oncodesign Precision Medicine (XPAR:ALOPM) Net Income

: €0.00 Mil (TTM As of Jun. 2022)

View and export this data going back to 2022. Start your Free Trial

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Oncodesign Precision Medicine's Net Income for the three months ended in Jun. 2022 was €0.00 Mil. Its Net Income for the trailing twelve months (TTM) ended in Jun. 2022 was €0.00 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Oncodesign Precision Medicine's Earnings per Share (Diluted) for the three months ended in Jun. 2022 was €0.00.

Oncodesign Precision Medicine Net Income Historical Data

The historical data trend for Oncodesign Precision Medicine's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine Annual Data

Trend

Dec20

Dec21

Net Income

-0.15

-2.94

Oncodesign Precision Medicine Quarterly Data
	Dec20	Mar21	Dec21	Jun22
Net Income	-	-	-	-

Oncodesign Precision Medicine Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Oncodesign Precision Medicine's Net Income for the fiscal year that ended in Dec. 2021 is calculated as

	Net Income		(A: Dec. 2021 )
=	Pre-Tax Income	+	Tax Provision	+	Net Income (Discontinued Operations)	+	Others
=	-4.079	+	1.135	+	0	+	0
=	-2.94

Oncodesign Precision Medicine's Net Income for the quarter that ended in Jun. 2022 is calculated as

	Net Income		(Q: Jun. 2022 )
=	Pre-Tax Income	+	Tax Provision	+	Net Income (Discontinued Operations)	+	Others
=	0	+	0	+	0	+	0
=	0.00

Net Income for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Oncodesign Precision Medicine (XPAR:ALOPM) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Oncodesign Precision Medicine's Earnings per Share (Diluted) (EPS) for the quarter that ended in Jun. 2022 is calculated as

Earnings per Share (Diluted) (Q: Jun. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(0	-	0)	/	6.851
	=	0.00

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.

Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.

Oncodesign Precision Medicine Net Income Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncodesign Precision Medicine (XPAR:ALOPM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Net Income

Comparable Companies

Traded in Other Exchanges

ZR8:Germany

Address

18 rue Jean Mazen, Dijon, FRA, 21000

Website

https://www.opm.oncodesign.com

Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine (XPAR:ALOPM) Headlines

No Headlines